Breakthroughs and Setbacks in the Fight Against Dengue Fever
Table of Contents
A potential turning point in the global battle against dengue fever arrived on November 26, with the approval of the world’s first single-dose vaccine and promising results from an oral antiviral treatment, though emerging drug resistance and stalled clinical trials present ongoing challenges.
More than 14 million people have been infected with dengue fever in 2024, making the mosquito-borne illness a significant public health threat. The newly approved vaccine, developed by the Butantan Institute, offers a crucial preventative measure, particularly in endemic regions. Simultaneously, research published in The New England Journal of Medicine (NEJM) details the success of mosnodenvir, an oral antiviral that dramatically reduced viral load in healthy volunteers experimentally infected with dengue serotype 3 (DENV-3). This marks the first demonstration of effective antiviral prophylaxis against the disease.
The study, utilizing a controlled human infection model (CHIM), involved healthy volunteers receiving a weakened and genetically stable DENV-3 virus. Researchers then compared the effects of three different doses of mosnodenvir against a placebo. The treatment protocol consisted of a five-day loading phase followed by 21 days of maintenance, with continuous monitoring of viral load and immune response. The primary measure of success was the area under the viral load curve between days one and 29, quantified through viral RNA measurement.
The results were striking. In the high-dose group, a remarkable 60% of participants (six out of ten) showed no signs of infection – meaning no detectable viral load, seroconversion, or associated symptoms – compared to zero percent in the placebo group. Furthermore, the viral load was significantly reduced in the high-dose group (p < 0.001). “These results confirm that inhibition of the NS3-NS4B interaction is a valid pharmacological target for an anti-DENV antiviral,” stated a senior researcher involved in the study.
Mosnodenvir was generally well-tolerated, with no serious adverse events reported in the small cohort. Plasma drug concentrations remained stable during the maintenance period. However, genomic sequencing revealed amino acid variation in the NS4B region of the viral genome in those receiving mosnodenvir – a potential indicator of viral selection and the beginnings of drug resistance.
Despite this concern, mosnodenvir holds promise as a prophylactic treatment, particularly at higher doses, for individuals in endemic areas or those traveling to regions with high dengue transmission rates. It could serve as a complement or alternative to vaccination.
The Shadow of Drug Resistance
However, the optimism surrounding mosnodenvir is tempered by the emergence of drug resistance. Recent genomic analyses reveal that dengue virus serotype 2 (DENV-2) strains, collected during the 2023-2024 epidemic in the French Antilles, exhibit an NS4B:V91A mutation. This mutation is associated with a greater than 1,000-fold reduction in sensitivity to mosnodenvir in vitro.
This isn’t an isolated incident. Drug-resistant lineages have surfaced multiple times over the past three decades in both DENV-2 and DENV-3, posing a significant threat to the antiviral’s long-term effectiveness against circulating viruses.
Setbacks and Ongoing Research
Adding to the complexity, Johnson & Johnson announced in October 2024 the termination of its phase 2 field study evaluating a dengue fever prevention strategy in naturally exposed adults. According to a company release, the decision was part of a broader strategic reorganization of its research and development portfolio, and was not related to safety concerns.
Despite this setback, research continues on multiple fronts. Novartis initiated a phase 2 trial last year for EYU688, a compound targeting a protein crucial for viral replication, with results expected in September 2026. The Serum Institute of India is also conducting a phase III trial with a monoclonal antibody treatment.
Despite the virological and strategic obstacles, research into dengue fever is accelerating and making significant progress. To be continued.
